By The Meals and Drug Administration mentioned in the present day that following yesterday’s constructive advisory committee assembly consequence relating to the Pfizer-BioNTech COVID-19 vaccine, it might quickly work towards finalization and issuance of an emergency use authorization for the COVID-19 vaccine.
The FDA gave no particular timeline.
The company has additionally notified the U.S. Facilities for Illness Management and Prevention and Operation Warp Velocity in order that they’ll execute their plans for well timed vaccine distribution.
HIMSS20 Digital
Study on-demand, earn credit score, discover merchandise and options. Get Began >>
Approval means vaccine distribution could be on Operation Warp Velocity’s schedule for distribution to frontline healthcare employees and susceptible populations in long-term care services by mid-month.
The FDA advisory committee has scheduled one other assembly to assessment the Moderna vaccine on Thursday, December 17.
See our persevering with vaccine protection right here:
Pfizer-BioNTech vaccine will get FDA advisory committee approval
CMS gives steering in billing Medicare for COVID-19 antibody remedy
1000’s in the UK are the primary to obtain Pfizer COVID-19 vaccine
Eli Lilly and UnitedHealth Group accomplice on COVID-19 antibody remedy for high-risk people
Operation Warp Velocity is trying to begin distributing COVID-19 vaccine by mid-month
Moderna seeks regulatory authorization for its COVID-19 vaccine
HHS will start allocating Regeneron’s COVID-19 therapeutic this week
HHS companions with chain and impartial pharmacies to extend entry to future COVID-19 vaccines
COVID-19 vaccine distribution will start inside 24 hours of an emergency use authorization
Moderna vaccine candidate exhibits 94.5% efficacy in opposition to COVID-19
Pfizer touts new COVID-19 vaccine, calling it ‘90% efficient’
Medicare beneficiaries can get monoclonal antibody COVID-19 remedies for gratis
FDA grants emergency use authorization for Eli Lilly antibody remedy for COVID-19
Twitter: @SusanJMorse
E mail the author: susan.morse@himssmedia.com
